Neurolentech, a drug discovery startup spun out of IST Austria and focused on epilepsy and related genetic neurodevelopmental disorders (NDDs), has announced the commencement of a technology access partnership with Kaerus Bioscience, a biotech company specialising in creating treatments for rare genetic neurodevelopmental syndromes.
The agreement enables Kaerus Bioscience to access Neurolentech’s NDD Drug Discovery platform and leverage its proprietary cell models and assays for functional screens.
Built for NDD drug discovery, Neurolentech's Platform comprises a vast collection of human-derived neuronal cell lines from patients with monogenic and complex neurodevelopmental disorders.
The Platform will enable Kaerus Bioscience to model the complex neural networks underlying clinical features of genetic NDDs at a cellular level, as well as to investigate the therapeutic potential of its small molecule pipeline for numerous genetic syndromes preclinically.
The partnership marks a significant milestone in Neurolentech’s mission to advance drug discovery for NDDs, and further reinforces its NDD Drug Discovery platform as a valuable resource for both researchers and industry partners.
